Conba Pharma (002773.SZ): Appoints Wang Ting as the Representative for Securities Affairs.

Gelonghui, March 5th - Kanghong Pharmaceuticals (002773.SZ) announced that Chengdu Kanghong Pharmaceutical Group Co., Ltd. convened the sixteenth meeting of its eighth board of directors on March 5, 2026. The meeting reviewed and approved the proposal 'Regarding the Appointment of the Company’s Securities Affairs Representative,' agreeing to appoint Ms. Wang Ting as the company’s securities affairs representative. Her term will commence from the date this proposal is passed by the board until the end of the term of the eighth board of directors.

Gelonghui FinanceMar 5 18:00

Express News | Conba Pharma: The company has been selected for the continuation procurement of drug varieties whose agreement period under the national centralized procurement program has expired.

BreakingsMar 1 16:24

Express News | Kanghong Pharmaceutical: Received approval notice for drug clinical trial

BreakingsFeb 25 17:48

BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials

PR NewswireFeb 9 21:00

Express News | Zhongtai Securities: Strategically optimistic about the API sector.

BreakingsFeb 5 07:53

First Coverage Report on Kanghong Pharmaceutical (002773): Deep Cultivation in the Golden Track of Ophthalmology, Gene Therapy Innovation Pipeline Opens New Horizons

As a leader in the field of ophthalmic innovative drugs, Kanghong Pharmaceutical has opened up long-term growth opportunities with its innovative pipeline. The company's product portfolio covers therapeutic areas including ophthalmology, psychiatry/neurology, gastroenterology, respiratory diseases, hypertension, and diabetes. Currently, the company is listed.

Cinda SecuritiesJan 19 00:00